Cargando…

Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene

Hepatocellular carcinoma (HCC) is an aggressive and chemoresistant cancer type. The development of novel therapeutic strategies is still urgently needed. Personalized or precision medicine is a new trend in cancer therapy, which treats cancer patients with specific genetic alterations. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Jiunn-Chang, Liu, Tsang-Pai, Andriani, Vivin, Athoillah, Muhammad, Wang, Chih-Yang, Yang, Pei-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623741/ https://www.ncbi.nlm.nih.gov/pubmed/34834551 http://dx.doi.org/10.3390/jpm11111199

Ejemplares similares

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics
por: Yang, Yang, et al.
Publicado: (2022)

Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report
por: Friemel, Juliane, et al.
Publicado: (2016)

CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study
por: Lin, Jiunn-Chang, et al.
Publicado: (2020)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

CSNK1E/CTNNB1 Are Synthetic Lethal To TP53 in Colorectal Cancer and Are Markers for Prognosis
por: Tiong, Khong-Loon, et al.
Publicado: (2014)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand
por: Galy, Olivier, et al.
Publicado: (2011)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Wild type p53 function in p53(Y220C) mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence
por: Sundar, Durai, et al.
Publicado: (2019)

Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells
por: Napolitano, Roberta, et al.
Publicado: (2020)

Frequency of somatic mutations in TERT promoter, TP53 and CTNNB1 genes in patients with hepatocellular carcinoma from Southern Italy
por: Lombardo, Daniele, et al.
Publicado: (2020)

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines
por: Davidson, Brittany Anne, et al.
Publicado: (2014)

Comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms’ tumor
por: He, Changjing, et al.
Publicado: (2020)

Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma
por: Kumar, Sonu, et al.
Publicado: (2023)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia
por: Kogan, Aksinija A., et al.
Publicado: (2022)

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA
por: Du, Kai-Xin, et al.
Publicado: (2023)

Erratum to comprehensive bioinformatics analysis of the TP53 signaling pathway in Wilms’ tumor
por: He, Changjing, et al.
Publicado: (2021)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Comparison of Modules of Wild Type and Mutant Huntingtin and TP53 Protein Interaction Networks: Implications in Biological Processes and Functions
por: Basu, Mahashweta, et al.
Publicado: (2013)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Impairment of rigidity sensing caused by mutant TP53 gain of function in osteosarcoma
por: Luo, Ming, et al.
Publicado: (2023)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma
por: Crippa, Stefania, et al.
Publicado: (2017)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
por: Haapaniemi, Emma, et al.
Publicado: (2019)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

NEK2, a promising target in TP53 mutant cancer
por: Cusan, Martina, et al.
Publicado: (2022)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

TP53 mutation status: emerging biomarker for precision radiation medicine?
por: Willers, Henning, et al.
Publicado: (2018)

Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report
por: Colombo, Carla, et al.
Publicado: (2022)

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p85kkh29qibhj7gp1nlfkbvha0